search
Back to results

Use of Probiotics as Adjunctive Treatment for Chronic Rhinosinusitis

Primary Purpose

Chronic Rhinosinusitis

Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
probiotic containing L.rhamnosus R0011 strain
Placebo
Sponsored by
University of Michigan
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Rhinosinusitis

Eligibility Criteria

15 Years - 70 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age ≥15 and ≤70 years.
  2. The patient must be bothered by each of the two following symptoms(>50% of days in the last 3 months):

    A. More than 12 consecutive weeks of symptomatic nasal obstruction and, B. More than 12 weeks of symptomatic nasal discharge.

  3. An Otolaryngologist evaluation and diagnosis of chronic inflammatory rhinosinusitis (hyperplastic mucosa, polyps in absence of overt bacterial infection)
  4. Access to telephone (home or person cell).

Exclusion Criteria:

  1. Sinus surgery within the last 3 months
  2. Acute illness within the last 2 weeks requiring antibiotics: including: otitis media, pharyngitis, bronchitis, or laryngitis.
  3. Immunosuppression (due to medications including oral steroids, or due to autoimmune diseases, HIV infection, cystic fibrosis, immunodeficiency, malignancies, uncontrolled diabetes mellitus, chronic renal failure, etc.)
  4. Patients with chronic or acute bacterial sinusitis.(Clinical diagnosis-to be decided by MD)
  5. An allergic reaction to a probiotic dietary supplement in the past (such as symptoms of tightness in the chest, breathing difficulties, skin hives, rash or other clinical symptoms consistent with sensitivity or intolerance)
  6. Inability to speak or read English.
  7. Pregnancy and Lactation

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Placebo Comparator

    Active Comparator

    Arm Label

    Placebo pill

    Probiotic

    Arm Description

    Placebo pills on same schedule as active intervention.

    L. rhamnosus R0011 strain

    Outcomes

    Primary Outcome Measures

    Mean Reduction in SNOT-20 Scores
    Mean reduction (and Standard deviation) in SNOT-20 scores, from baseline to 8 week measurements. SinoNasal Outcome Test measures symptom severity. It is a summary score, ranging from 0 to 100 with 100 indicating worse symptoms. Since 100 represents more severe symptoms, the changes represented here are reductions in SNOT-scores, even though they are not expressed as negative numbers.

    Secondary Outcome Measures

    Side Effect Summary
    Totals of all side effects for placebo group and treatment group over the course of the eight week trial (including patients who dropped from the study after baseline measurement). Individual categories of side-effects are listed in Adverse events section.
    Mean Number of Days of Antibiotic Use During the Study Period (0-8 Weeks)
    Mean number of days that antibiotics were used in the subgroup (placebo vs Probiotic arm)
    Mean Number of Days of Steroid Spray Use for Each Group

    Full Information

    First Posted
    November 2, 2006
    Last Updated
    August 11, 2016
    Sponsor
    University of Michigan
    Collaborators
    Institut Rosell
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00396162
    Brief Title
    Use of Probiotics as Adjunctive Treatment for Chronic Rhinosinusitis
    Official Title
    Use of Probiotics as Adjunctive Treatment for Chronic Rhinosinusitis
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2016
    Overall Recruitment Status
    Completed
    Study Start Date
    November 2006 (undefined)
    Primary Completion Date
    January 2008 (Actual)
    Study Completion Date
    February 2008 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    University of Michigan
    Collaborators
    Institut Rosell

    4. Oversight

    5. Study Description

    Brief Summary
    Chronic sinusitis is reported to be one of the most widespread disorders in the United States. It can be caused by a variety of reasons such as allergy, infection and/or defects in T-cells which help regulate immune function. Medication and other costs related to treatment of nasal and sinus infections are estimated to be more than $60 million annually putting a considerable strain on the economy of health care. Probiotics are live microorganisms that are normally present in the gut of a healthy individual. They are also known as "friendly bacteria" and have been used to help maintain the normal functioning of the immune system. They are safe and are commercially available in the form of yoghurt, sachets, chewable tablets or flavored capsules. Since a number of nasal and sinus disorders are related to allergy and improper functioning of the immune system, we hypothesize that regular use of probiotics may help improve chronic nasal and sinus symptoms by boosting immune responses. The project we propose is novel because it would be the first study evaluating the usefulness of probiotics for the larger population having chronic sinusitis rather than those having only allergic symptoms. We aim to assess whether regular use of probiotics will help improve symptoms of chronic sinusitis and will have a greater effect than placebo in this regard.
    Detailed Description
    Probiotics are live microorganisms which when administered in adequate amounts confer a health benefit on the host. They are a part of the normal gastrointestinal flora and have safely been used to boost immune responses in patients with perennial and seasonal allergic rhinitis. Their exact mechanism of benefit is unknown but they primarily help to regulate T-cell function which is important in maintaining immune tolerance. Chronic rhinosinusitis is widely prevalent and affects nearly 16 million people in the US alone each year. It puts a strain on the health resources of the nation in terms of costs related to medications and surgery. Chronic rhinosinusitis can be caused by a variety of reasons including allergy/hypersensitivity, infection, nasal anatomical variations and T-cell regulatory dysfunction. We hypothesize that regular use of probiotics in patients with chronic rhinosinusitis will result in substantial improvement in their symptoms by boosting their immunity and may also help decrease their medication usage. Our study will be a double-blinded, randomized, control trial. We hope to recruit 100 patients from the University Otolaryngology and Allergy Clinics. Fifty patients will be randomized to the treatment (active) arm and 50 patients to the placebo arm. Subjects will be followed for 2 months during their period of participation in the study. The main aim of our study is to determine whether regular use of probiotics in patients with chronic rhinosinusitis helps improve their quality of life. Our main outcome of interest is a change in the mean score of the Sino-Nasal Outcome Test (SNOT-20) form in the treatment group and a greater change in the mean score of the SNOT-20 in the treatment arm as compared to the placebo arm. If probiotics are found to be effective, they may be used as a cost-effective, adjunctive therapy for patients with chronic rhinosinusitis.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Chronic Rhinosinusitis

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigator
    Allocation
    Randomized
    Enrollment
    77 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Placebo pill
    Arm Type
    Placebo Comparator
    Arm Description
    Placebo pills on same schedule as active intervention.
    Arm Title
    Probiotic
    Arm Type
    Active Comparator
    Arm Description
    L. rhamnosus R0011 strain
    Intervention Type
    Drug
    Intervention Name(s)
    probiotic containing L.rhamnosus R0011 strain
    Other Intervention Name(s)
    L rhamnosus R0011
    Intervention Description
    500 million active cells of L rhamnosus R0011 strain per tablet bid for 4 weeks
    Intervention Type
    Other
    Intervention Name(s)
    Placebo
    Intervention Description
    Placebo pill
    Primary Outcome Measure Information:
    Title
    Mean Reduction in SNOT-20 Scores
    Description
    Mean reduction (and Standard deviation) in SNOT-20 scores, from baseline to 8 week measurements. SinoNasal Outcome Test measures symptom severity. It is a summary score, ranging from 0 to 100 with 100 indicating worse symptoms. Since 100 represents more severe symptoms, the changes represented here are reductions in SNOT-scores, even though they are not expressed as negative numbers.
    Time Frame
    8 weeks
    Secondary Outcome Measure Information:
    Title
    Side Effect Summary
    Description
    Totals of all side effects for placebo group and treatment group over the course of the eight week trial (including patients who dropped from the study after baseline measurement). Individual categories of side-effects are listed in Adverse events section.
    Time Frame
    8 weeks
    Title
    Mean Number of Days of Antibiotic Use During the Study Period (0-8 Weeks)
    Description
    Mean number of days that antibiotics were used in the subgroup (placebo vs Probiotic arm)
    Time Frame
    At 8 weeks after baseline measures
    Title
    Mean Number of Days of Steroid Spray Use for Each Group
    Time Frame
    8 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    15 Years
    Maximum Age & Unit of Time
    70 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Age ≥15 and ≤70 years. The patient must be bothered by each of the two following symptoms(>50% of days in the last 3 months): A. More than 12 consecutive weeks of symptomatic nasal obstruction and, B. More than 12 weeks of symptomatic nasal discharge. An Otolaryngologist evaluation and diagnosis of chronic inflammatory rhinosinusitis (hyperplastic mucosa, polyps in absence of overt bacterial infection) Access to telephone (home or person cell). Exclusion Criteria: Sinus surgery within the last 3 months Acute illness within the last 2 weeks requiring antibiotics: including: otitis media, pharyngitis, bronchitis, or laryngitis. Immunosuppression (due to medications including oral steroids, or due to autoimmune diseases, HIV infection, cystic fibrosis, immunodeficiency, malignancies, uncontrolled diabetes mellitus, chronic renal failure, etc.) Patients with chronic or acute bacterial sinusitis.(Clinical diagnosis-to be decided by MD) An allergic reaction to a probiotic dietary supplement in the past (such as symptoms of tightness in the chest, breathing difficulties, skin hives, rash or other clinical symptoms consistent with sensitivity or intolerance) Inability to speak or read English. Pregnancy and Lactation
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Jeffrey E Terrell, MD
    Organizational Affiliation
    University of Michigan
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Use of Probiotics as Adjunctive Treatment for Chronic Rhinosinusitis

    We'll reach out to this number within 24 hrs